NEW YORK, Sept. 16, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Keryx Biopharmaceuticals, Inc. securities (NASDAQ:KERX) from February 25, 2016 through August 1, 2016, both dates inclusive (the “Class Period”) of the important October 3, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Keryx Biopharmaceuticals investors under the federal securities laws.
To join the Keryx Biopharmaceuticals class action, go to the firm’s website at http://rosenlegal.com/cases-927.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Keryx Biopharmaceuticals was experiencing production-related difficulties in converting API to finished drug product; (2) the issue was resulting in decreased production yields of finished drug product; and (3) as a result, defendants’ statements about Keryx Biopharmaceuticals’ business and operations were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 3, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-927.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Apple Turns 50: From Garage Startup to AI Crossroads
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



